Cryo-Cell International, Inc. (CCEL) - 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for Cryo-Cell International, Inc. for the period ended August 31, 2025. The Company operates in three segments: private cord blood and tissue storage, manufacturing of PrepaCyte CB processing units, and public cord blood banking. As of August 31, 2025, the Company stored over 240,000 specimens. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Aug 31, 2025 | Nine Months Ended Aug 31, 2025 | Nine Months Ended Aug 31, 2024 |
|---|---|---|---|
| Total Revenue | $7,825,432 | $23,723,155 | $23,961,761 |
| Net Income | $749,408 | $1,388,048 | $2,263,710 |
| Operating Income | $1,900,536 | $4,449,181 | $3,602,631 |
| Net Cash from Operating Activities | N/A | $4,197,793 | $3,853,917 |
| Cash and Cash Equivalents (Ending) | $265,207 | $265,207 | $197,437 |
| Total Debt (Current + Long-Term) | $3,558,374 | $11,585,955 | $11,830,533 |
| Stockholders' Deficit | ($14,831,399) | ($14,831,399) | ($9,558,956) |
Note: Total Debt includes Line of Credit ($3.2M), Note Payable ($8.5M), and current portion of note ($0.18M). Stockholders' deficit reflects an accumulated deficit of $34.6M.
Material Changes vs. Prior Period
- Revenue: Nine-month revenue decreased slightly by 1% ($23.7M vs. $24.0M). This was driven by a 14% decrease in new domestic cord blood specimens processed, partially offset by a 3% increase in recurring annual storage fees. Public banking revenue dropped significantly to $128,886 from $205,799 due to demand volatility.
- Profitability: Net income for the nine months decreased 39% to $1.39M from $2.26M. This decline is primarily attributed to a $1.66M swing in marketable securities (from a $1.06M gain in 2024 to a $0.60M loss in 2025) and increased interest expense ($1.58M vs. $1.12M).
- Expenses: Selling, General, and Administrative (SG&A) expenses increased 2% year-over-year, largely due to a $604,000 increase in legal fees related to ongoing litigation. Research and Development expenses decreased significantly to $291,479 from $937,907, as funding for the Duke IMPACT Study ceased.
- Liquidity: Cash and cash equivalents decreased by $295,753 during the nine-month period. Financing activities consumed $3.8M, primarily due to $3.2M in cash dividends paid and debt repayments, partially offset by $6.8M in line of credit proceeds.
Guidance, Outlook, and Risks
- Duke University Dispute: The Company is engaged in a material arbitration with Duke University regarding a Patent and Technology License Agreement. Duke terminated the agreement on May 17, 2025. The Company alleges fraudulent inducement and breach of contract, seeking damages exceeding $100 million. Duke has asserted counterclaims. A final hearing is scheduled for April 2026.
- Strategic Impact: Due to the Duke dispute, the Company has paused the opening of the Cryo-Cell Institute for Cellular Therapies and placed the proposed spinoff of its subsidiary, Celle Corp., on hold. The Company does not anticipate further investment in Duke-related activities until the dispute is resolved.
- Capital Needs: The Company anticipates funding known cash needs for the next 12 months through cash on hand, marketable securities, operating cash flows, and its revolving line of credit. However, future capital requirements for clinical trials or biopharmaceutical manufacturing remain uncertain pending the arbitration outcome.
- Dividends: The Company paid cash dividends totaling $0.40 per share during the nine-month period ($0.25 in Feb 2025 and $0.15 in May 2025).
Investor Verification Checklist
- Arbitration Status: Verify the current status of the arbitration against Duke University and the potential impact on the $100M+ damages claim and counterclaims.
- License Termination: Confirm the operational impact of Duke's termination of the License Agreement on the Company's ability to commercialize cellular therapies and the status of the Celle Corp. spinoff.
- Debt Covenants: Review the Company's compliance with debt covenants (Leverage Ratio < 3.50:1, Debt Service Coverage Ratio > 1.25:1) given the stockholders' deficit and interest expense levels.
- Revenue Mix: Monitor the trend of new domestic enrollments versus recurring storage fees, as new enrollments declined 14% year-over-year.
- Legal Fees: Assess the sustainability of SG&A expenses given the $604,000 increase in legal fees related to the Duke and Lehr litigation matters.